Developer docs
API playgroundTry for free, no card

Search company profiles

PharmAbcine

Full company profile

uuid000csh6

Namestring
PharmAbcine
Legal namestring
PharmAbcine Inc.
Websiteurl
pharmabcine.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

PharmAbcine is a clinical-stage biotechnology company headquartered in Daejeon, South Korea, that develops fully human therapeutic monoclonal antibodies for cancer, vascular eye diseases, and vascular-related conditions. The company's pipeline is built on its proprietary HuPhage Display fully human antibody library, which enables discovery of differentiated biologics with novel mechanisms of action. Core clinical assets include Olinvacimab (a VEGFR2-neutralizing antibody in Phase 2 for metastatic triple-negative breast cancer in combination with pembrolizumab), PMC-309 (a first-in-class anti-VISTA immune checkpoint antibody in Phase 1a/b for advanced or metastatic solid tumors in Australia), and PMC-403 (a TIE2-activating antibody that completed Phase 1 for chronic wet AMD and holds FDA Orphan Drug Designation for Systemic Capillary Leak Syndrome). Additional pipeline assets include PMC-402 and preclinical PMC-005, an anti-EGFRviii antibody positioned for CAR-T, CAR-NK, and radioimmunotherapy modalities.

The company's business model is licensing-out: it advances novel antibody candidates through clinical and preclinical development and seeks global biopharmaceutical partners for late-stage development and commercialization. Strategic partners include MSD/Merck (clinical supply of Keytruda for combination trials and joint patent filing), Aprogen (out-licensee of PMC-309), Samsung Biologics (contract manufacturing), and Arontier Inc. (AI-driven antibody platform collaboration). PharmAbcine operates wholly-owned subsidiaries Wincal BioPharm in the United States, focused on an eye-drop delivery platform, and PharmAbcine Australia Pty, supporting clinical operations. The company is publicly listed on KOSDAQ under ticker 208340/203840, with 11–50 employees and no commercialized products; its revenue derives from licensing milestones, government grants (KDDF), and capital markets activity.

Short descriptiontext

PharmAbcine is a clinical-stage South Korean biotech developing fully human monoclonal antibodies for cancer and ophthalmology indications, pursuing a licensing-out model with global biopharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDaejeon, South Korea
HQ citystring
Daejeon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, monoclonal antibody development, immuno-oncology biologics, clinical-stage biotech, ophthalmology antibody drugs
Industry4 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals / Antibody Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Revenue
TypeLicensing Royalties
Description

PharmAbcine's primary business model is to develop novel antibody therapeutics and license them out to global biopharma companies. The company develops candidates through clinical stages and seeks licensing partnerships for commercialization.

pharmabcine.com
2Out-licensed PMC-309 to Aprogen
TypeLicensing Royalties
Description

PharmAbcine recently out-licensed PMC-309 to Aprogen (www.aprogen.com), representing a revenue-generating licensing transaction for their VISTA-targeting immune checkpoint inhibitor candidate.

pharmabcine.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PharmAbcine is a clinical-stage biotechnology company that discovers and develops fully human therapeutic monoclonal antibodies using its proprietary HuPhage Display platform, with a pipeline targeting cancer, inflammatory diseases, and ophthalmology indications. Its lead candidates include Olinvacimab (anti-VEGFR2), PMC-309 (anti-VISTA), PMC-403 (TIE2-activating), PMC-402, and PMC-005, developed either for direct clinical advancement or for out-licensing to global biopharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • PMC-403 demonstrated favorable tolerability and predictable safety profile with no dose-limiting toxicities or major safety concerns in Phase 1 trial for chronic wet AMD patients
+2 more records
Product overview1 text field

PharmAbcine is a clinical-stage biotech company developing a portfolio of novel antibody therapeutics based on its proprietary HuPhage Display fully human antibody platform. The company focuses on three core clinical-stage assets: Olinvacimab (VEGFR2-neutralizing antibody in Phase 2 for mTNBC), PMC-309 (anti-VISTA antibody in Phase 1 for solid tumors), and PMC-403 (TIE2-activating antibody successfully completing Phase 1 for wet AMD). Additional pipeline products include PMC-402 and PMC-005 (anti-EGFRviii for CAR-T applications). Through its U.S. subsidiary Wincal BioPharm, the company is developing an eye-drop platform to replace intravitreal injections. The company leverages its AI-driven antibody development platform developed in partnership with Arontier.

Product and service6 records
1Olinvacimab (PMC-501)
CategoryAntibody Therapeutics / Oncology
Description

Anti-VEGFR2 fully human monoclonal antibody being developed for oncology indications; the company's lead clinical-stage asset, offered to biopharma partners for licensing and co-development.

2PMC-309
CategoryAntibody Therapeutics / Immuno-Oncology
Description

Anti-VISTA fully human monoclonal antibody candidate targeting the VISTA immune checkpoint for immuno-oncology applications; offered for licensing to global biopharmaceutical partners.

3PMC-403
CategoryAntibody Therapeutics / Ophthalmology
Description

TIE2-activating fully human monoclonal antibody candidate being developed for ophthalmology and vascular-related indications, with potential applications enabled by the company's non-ophthalmic eye-drop delivery technology.

4PMC-402
CategoryAntibody Therapeutics
Description

Early-stage pipeline antibody candidate discovered via PharmAbcine's HuPhage Display platform, in development for therapeutic applications.

5PMC-005
CategoryAntibody Therapeutics
Description

Early-stage pipeline antibody candidate discovered via PharmAbcine's HuPhage Display platform, in development for therapeutic applications.

6Wincal BioPharm non-ophthalmic eye-drop delivery platform
CategoryOphthalmic Drug Delivery Technology
Description

Proprietary non-ophthalmic eye-drop antibody delivery technology operated through US subsidiary Wincal BioPharm, enabling topical ocular delivery of antibody therapeutics without intravitreal injection; offered to partners developing ophthalmology biologics.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-02-10
Description

Partnership to jointly develop an AI-based antibody innovation drug development platform, converging AI and antibody data to create a new paradigm for antibody-based drug discovery. Arontier brings strong foundation in AI-driven drug discovery.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-12
Description

Research collaboration agreement for antibody-based drug development.

3FutureChem
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-09-22
Description

Signed MoU to explore possibilities of developing novel radiopharmaceuticals.

pharmabcine.com
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2020-04-07
Description

Development and manufacturing partnership for oncology and neovascular treatment antibody therapeutics. Samsung Biologics provides contract development and manufacturing services for PharmAbcine's pipeline candidates including PMC-403.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MSD provides Keytruda (pembrolizumab) free of charge for combination therapy trials with PharmAbcine's olinvacimab (for mTNBC) and PMC-309 (for solid tumors). MSD has been invited to the MSD@JPM Dinner Reception and extended clinical collaboration agreements.

6Dr. Kirk Druey (NIH)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration with former Chief of NIH's Lung and Vascular Inflammation Section to explore PMC-403's efficacy in animal models for Idiopathic Systemic Capillary Leak Syndrome (SCLS/Clarkson disease).

pharmabcine.com
7Wincal BioPharm (U.S. Subsidiary)
Strategic tierCoreTypeOthers
Description

U.S.-based subsidiary developing a new eye-drop platform intended to replace existing intravitreal injection therapies. Led by CSO TaeWeon Lee. Selected for oral presentation at ARVO 2024.

pharmabcine.com
8Prof. Quan Dong Nguyen (Stanford University)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Professor at Stanford University School of Medicine who plays a key role in PharmAbcine's ophthalmology therapeutics division through Wincal BioPharm collaboration.

pharmabcine.com
9Binex
Strategic tierMinorTypeOthers
Description

CMO (Contract Manufacturing Organization) contract with Binex to produce olinvacimab at its new 5,000L production line.

pharmabcine.com
10WuXi Shuangliang Biotechnology (SLBio)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration agreement to evaluate combination therapy to treat NSCLC (non-small cell lung cancer).

pharmabcine.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Korean clinical-stage biotech developing novel biologics (including antibody and fusion protein platforms) for oncology and autoimmune indications. Comparable Korean biotech peer with similar clinical-stage profile and out-licensing orientation.

TypeOthers
Description

Global biologics CDMO providing end-to-end antibody development and manufacturing services. Serves as a comparable ecosystem/development partner rather than a direct therapeutic competitor.

TypeBroad incumbent
Description

Major Korean biologics company with a broad biosimilars and novel biologics portfolio. Operates at much larger scale with manufacturing infrastructure, serving as a benchmark for Korean antibody/biologics commercialization.

TypeOthers
Description

Global CDMO providing contract development and manufacturing services for PharmAbcine's antibody candidates. Operates as a service provider rather than competing product developer but is closely tied via manufacturing partnership.

TypeDirect peer
Description

Pioneering antibody therapeutics company with proprietary platforms (DuoBody bispecifics, Hexabody) and broad oncology partnerships with major pharma. Highly comparable as a technology-and-licensing-driven antibody developer targeting oncology.

TypeBroad incumbent
Description

Global leader in therapeutic antibodies (Eylea, Dupixent, Libtayo IO franchise) using proprietary VelociSuite platforms. Broad incumbent in antibody therapeutics including anti-VEGF ophthalmology and oncology where PharmAbcine competes.

TypeDirect peer
Description

US clinical-stage biotech developing monoclonal antibodies in immuno-oncology, notably with an anti-VISTA program targeting the same myeloid checkpoint as PharmAbcine's PMC-309. Most directly comparable peer given shared VISTA target and overlapping oncology indications.

TypeBroad incumbent
Description

Major South Korean pharmaceutical company with biologics and antibody pipeline targeting oncology, ophthalmology, and autoimmune indications. Larger incumbent operating broadly in adjacent therapeutic categories.

TypeDirect peer
Description

Korean biotech developing antibody-based therapeutics including antibody-drug conjugates, with active collaboration agreement with PharmAbcine. Geographic and therapeutic category peer in the Korean biotech ecosystem.

TypeEmerging player
Description

Korean biotech that licensed PharmAbcine's PMC-309 for further development and commercialization. As a downstream development partner on the same asset, Aprogen occupies an emerging/biopharma space overlapping the same anti-VISTA target.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmAbcine

Biopharmaceuticals / Antibody Therapeuticspharmabcine.com

PharmAbcine is a clinical-stage South Korean biotech developing fully human monoclonal antibodies for cancer and ophthalmology indications, pursuing a licensing-out model with global biopharmaceutical partners.

What PharmAbcine does

PharmAbcine is a clinical-stage biotechnology company headquartered in Daejeon, South Korea, that develops fully human therapeutic monoclonal antibodies for cancer, vascular eye diseases, and vascular-related conditions. The company's pipeline is built on its proprietary HuPhage Display fully human antibody library, which enables discovery of differentiated biologics with novel mechanisms of action. Core clinical assets include Olinvacimab (a VEGFR2-neutralizing antibody in Phase 2 for metastatic triple-negative breast cancer in combination with pembrolizumab), PMC-309 (a first-in-class anti-VISTA immune checkpoint antibody in Phase 1a/b for advanced or metastatic solid tumors in Australia), and PMC-403 (a TIE2-activating antibody that completed Phase 1 for chronic wet AMD and holds FDA Orphan Drug Designation for Systemic Capillary Leak Syndrome). Additional pipeline assets include PMC-402 and preclinical PMC-005, an anti-EGFRviii antibody positioned for CAR-T, CAR-NK, and radioimmunotherapy modalities.

The company's business model is licensing-out: it advances novel antibody candidates through clinical and preclinical development and seeks global biopharmaceutical partners for late-stage development and commercialization. Strategic partners include MSD/Merck (clinical supply of Keytruda for combination trials and joint patent filing), Aprogen (out-licensee of PMC-309), Samsung Biologics (contract manufacturing), and Arontier Inc. (AI-driven antibody platform collaboration). PharmAbcine operates wholly-owned subsidiaries Wincal BioPharm in the United States, focused on an eye-drop delivery platform, and PharmAbcine Australia Pty, supporting clinical operations. The company is publicly listed on KOSDAQ under ticker 208340/203840, with 11–50 employees and no commercialized products; its revenue derives from licensing milestones, government grants (KDDF), and capital markets activity.

PharmAbcine firmographics

Firmographics
Name
PharmAbcine
Legal name
PharmAbcine Inc.
Website
https://pharmabcine.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
PharmAbcine is a clinical-stage South Korean biotech developing fully human monoclonal antibodies for cancer and ophthalmology indications, pursuing a licensing-out model with global biopharmaceutical partners.
Ownership category
akta.pro rank

PharmAbcine industry classification

Industry
Product category
Biopharmaceuticals / Antibody Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody therapeutics
  • Monoclonal antibody development
  • Immuno-oncology biologics
  • Clinical-stage biotech
  • Ophthalmology antibody drugs

Where PharmAbcine is headquartered

Location

Headquarters

HQ city
Daejeon
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

PharmAbcine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing Revenue: PharmAbcine's primary business model is to develop novel antibody therapeutics and license them out to global biopharma companies. The company develops candidates through clinical stages and seeks licensing partnerships for commercialization.
  2. Out-licensed PMC-309 to Aprogen: PharmAbcine recently out-licensed PMC-309 to Aprogen (www.aprogen.com), representing a revenue-generating licensing transaction for their VISTA-targeting immune checkpoint inhibitor candidate.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

PharmAbcine product offering

Product offering

Core offering

PharmAbcine is a clinical-stage biotechnology company that discovers and develops fully human therapeutic monoclonal antibodies using its proprietary HuPhage Display platform, with a pipeline targeting cancer, inflammatory diseases, and ophthalmology indications. Its lead candidates include Olinvacimab (anti-VEGFR2), PMC-309 (anti-VISTA), PMC-403 (TIE2-activating), PMC-402, and PMC-005, developed either for direct clinical advancement or for out-licensing to global biopharmaceutical partners.

Product overview

PharmAbcine is a clinical-stage biotech company developing a portfolio of novel antibody therapeutics based on its proprietary HuPhage Display fully human antibody platform. The company focuses on three core clinical-stage assets: Olinvacimab (VEGFR2-neutralizing antibody in Phase 2 for mTNBC), PMC-309 (anti-VISTA antibody in Phase 1 for solid tumors), and PMC-403 (TIE2-activating antibody successfully completing Phase 1 for wet AMD). Additional pipeline products include PMC-402 and PMC-005 (anti-EGFRviii for CAR-T applications). Through its U.S. subsidiary Wincal BioPharm, the company is developing an eye-drop platform to replace intravitreal injections. The company leverages its AI-driven antibody development platform developed in partnership with Arontier.

Differentiator

Problem solved

Functional benefit

Products and services

  • Olinvacimab (PMC-501) Anti-VEGFR2 fully human monoclonal antibody being developed for oncology indications; the company's lead clinical-stage asset, offered to biopharma partners for licensing and co-development.
  • PMC-309 Anti-VISTA fully human monoclonal antibody candidate targeting the VISTA immune checkpoint for immuno-oncology applications; offered for licensing to global biopharmaceutical partners.
  • PMC-403 TIE2-activating fully human monoclonal antibody candidate being developed for ophthalmology and vascular-related indications, with potential applications enabled by the company's non-ophthalmic eye-drop delivery technology.
  • PMC-402 Early-stage pipeline antibody candidate discovered via PharmAbcine's HuPhage Display platform, in development for therapeutic applications.
  • PMC-005 Early-stage pipeline antibody candidate discovered via PharmAbcine's HuPhage Display platform, in development for therapeutic applications.
  • Wincal BioPharm non-ophthalmic eye-drop delivery platform Proprietary non-ophthalmic eye-drop antibody delivery technology operated through US subsidiary Wincal BioPharm, enabling topical ocular delivery of antibody therapeutics without intravitreal injection; offered to partners developing ophthalmology biologics.

Quantifiable outcome

  • PMC-403 demonstrated favorable tolerability and predictable safety profile with no dose-limiting toxicities or major safety concerns in Phase 1 trial for chronic wet AMD patients
  • +2 more outcomes

Companies that use PharmAbcine

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

PharmAbcine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

PharmAbcine partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered strategic, minor and core.

  • Arontier Inc.strategicTechnology or Integration · 10 February 2025Partnership to jointly develop an AI-based antibody innovation drug development platform, converging AI and antibody data to create a new paradigm for antibody-based drug discovery. Arontier brings strong foundation in AI-driven drug discovery.
  • LegoChem BiosciencesminorStrategic or Co-development Partner · 12 January 2021Research collaboration agreement for antibody-based drug development.
  • FutureChemminorStrategic or Co-development Partner · 22 September 2020Signed MoU to explore possibilities of developing novel radiopharmaceuticals.
  • Samsung BiologicscoreImplementation/ SI/ Consulting Partner · 7 April 2020Development and manufacturing partnership for oncology and neovascular treatment antibody therapeutics. Samsung Biologics provides contract development and manufacturing services for PharmAbcine's pipeline candidates including PMC-403.
  • MSD (Merck)coreStrategic or Co-development PartnerMSD provides Keytruda (pembrolizumab) free of charge for combination therapy trials with PharmAbcine's olinvacimab (for mTNBC) and PMC-309 (for solid tumors). MSD has been invited to the MSD@JPM Dinner Reception and extended clinical collaboration agreements.
  • Dr. Kirk Druey (NIH)minorStrategic or Co-development PartnerResearch collaboration with former Chief of NIH's Lung and Vascular Inflammation Section to explore PMC-403's efficacy in animal models for Idiopathic Systemic Capillary Leak Syndrome (SCLS/Clarkson disease).
  • Wincal BioPharm (U.S. Subsidiary)coreOthersU.S.-based subsidiary developing a new eye-drop platform intended to replace existing intravitreal injection therapies. Led by CSO TaeWeon Lee. Selected for oral presentation at ARVO 2024.
  • Prof. Quan Dong Nguyen (Stanford University)minorStrategic or Co-development PartnerProfessor at Stanford University School of Medicine who plays a key role in PharmAbcine's ophthalmology therapeutics division through Wincal BioPharm collaboration.
  • BinexminorOthersCMO (Contract Manufacturing Organization) contract with Binex to produce olinvacimab at its new 5,000L production line.
  • WuXi Shuangliang Biotechnology (SLBio)minorStrategic or Co-development PartnerResearch collaboration agreement to evaluate combination therapy to treat NSCLC (non-small cell lung cancer).

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

PharmAbcine competitors and assessment

Company assessment

Broad incumbents

  • Genexine: Korean clinical-stage biotech developing novel biologics (including antibody and fusion protein platforms) for oncology and autoimmune indications. Comparable Korean biotech peer with similar clinical-stage profile and out-licensing orientation.
  • Celltrion: Major Korean biologics company with a broad biosimilars and novel biologics portfolio. Operates at much larger scale with manufacturing infrastructure, serving as a benchmark for Korean antibody/biologics commercialization.
  • Regeneron Pharmaceuticals: Global leader in therapeutic antibodies (Eylea, Dupixent, Libtayo IO franchise) using proprietary VelociSuite platforms. Broad incumbent in antibody therapeutics including anti-VEGF ophthalmology and oncology where PharmAbcine competes.
  • Hanmi Pharmaceutical: Major South Korean pharmaceutical company with biologics and antibody pipeline targeting oncology, ophthalmology, and autoimmune indications. Larger incumbent operating broadly in adjacent therapeutic categories.

Others

  • WuXi Biologics: Global biologics CDMO providing end-to-end antibody development and manufacturing services. Serves as a comparable ecosystem/development partner rather than a direct therapeutic competitor.
  • Samsung Biologics: Global CDMO providing contract development and manufacturing services for PharmAbcine's antibody candidates. Operates as a service provider rather than competing product developer but is closely tied via manufacturing partnership.

Direct peers

  • Genmab: Pioneering antibody therapeutics company with proprietary platforms (DuoBody bispecifics, Hexabody) and broad oncology partnerships with major pharma. Highly comparable as a technology-and-licensing-driven antibody developer targeting oncology.
  • MacroGenics: US clinical-stage biotech developing monoclonal antibodies in immuno-oncology, notably with an anti-VISTA program targeting the same myeloid checkpoint as PharmAbcine's PMC-309. Most directly comparable peer given shared VISTA target and overlapping oncology indications.
  • LegoChem Biosciences: Korean biotech developing antibody-based therapeutics including antibody-drug conjugates, with active collaboration agreement with PharmAbcine. Geographic and therapeutic category peer in the Korean biotech ecosystem.

Emerging players

  • Aprogen: Korean biotech that licensed PharmAbcine's PMC-309 for further development and commercialization. As a downstream development partner on the same asset, Aprogen occupies an emerging/biopharma space overlapping the same anti-VISTA target.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

PharmAbcine social profiles

Digital presence

PharmAbcine compliance and trust

Trust signal

Compliance1 record

PharmAbcine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmAbcine leadership team

Management profile

Number of profiles

Profiles7 records

PharmAbcine subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

PharmAbcine funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmAbcine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmAbcine

What does PharmAbcine do?

PharmAbcine is a clinical-stage biotechnology company that discovers and develops fully human therapeutic monoclonal antibodies using its proprietary HuPhage Display platform, with a pipeline targeting cancer, inflammatory diseases, and ophthalmology indications. Its lead candidates include Olinvacimab (anti-VEGFR2), PMC-309 (anti-VISTA), PMC-403 (TIE2-activating), PMC-402, and PMC-005, developed either for direct clinical advancement or for out-licensing to global biopharmaceutical partners.

Is PharmAbcine a public or private company?

PharmAbcine is a public company. It is classified as public and is currently operating.

When was PharmAbcine founded?

PharmAbcine was founded in 2008. It employs 11 to 50 people.

Where is PharmAbcine based?

PharmAbcine is headquartered in Daejeon, South Korea, in the Asia region.

How does PharmAbcine make money?

Two revenue lines are on record. Licensing Revenue is the primary driver. The others are out-licensed PMC-309 to Aprogen.

Who are PharmAbcine's main competitors?

Broad incumbents on record are Genexine, Celltrion, Regeneron Pharmaceuticals and Hanmi Pharmaceutical. Others are WuXi Biologics and Samsung Biologics. Direct peers are Genmab, MacroGenics and LegoChem Biosciences. Aprogen is listed as an emerging player.

Does PharmAbcine have an API?

No public API is recorded for PharmAbcine.

What industry is PharmAbcine in?

PharmAbcine's product category is Biopharmaceuticals / Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooVISTA Inhibitor Market Insights Report 2026 | Featuring Profiles of Aurigene Discovery Technologies, Curis, Hummingbird Bioscience, Kineta, PharmAbcineResearchAndMarkets.com added a report on the global VISTA inhibitor market, covering drivers, risks, clinical milestones, regional innovation and competitive positioning. The report notes no VISTA inhibitor has received regulatory approval as of June 2026, with candidates in clinical development across oncology indications. It assesses the possibility of the first approval by 2029.PR NewswirePharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024PharmAbcine's U.S. subsidiary Wincal Biopharm presented preclinical data at ARVO 2024, demonstrating that its proprietary Ocular Penetration Carrier (OPC) platform can deliver anti-VEGF antibody treatments including Eylea (aflibercept) and Beovu (brolucizumab) as non-invasive eye drops. In animal studies using a laser-induced choroid neovascularization mouse model, the OPC eye drop formulations showed similar efficacy in reducing lesion size and vascular leakage compared to traditional intravitreal injections. The company plans to advance the technology through primate efficacy studies and clinical trials, with executives noting potential for attracting VC investment and corporate partnerships in the biopharma sector.PR NewswirePharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and OphthalmoPharmAbcine's U.S. subsidiary Wincal Biopharm will present preclinical findings on its proprietary Ocular Penetration Carrier (OPC) platform at the ARVO 2024 conference in Seattle, May 5-9, 2024. The platform enables delivery of antibody therapeutics via eyedrops instead of intravitreal injections for treating posterior ocular diseases including age-related macular degeneration (AMD) and diabetic macular edema (DME). Preclinical efficacy has been demonstrated in mouse CNV models, with clinical studies planned for 2026.PR NewswirePharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMDPharmAbcine Inc. received Investigational New Drug (IND) approval from the Korean Ministry of Food and Drug Safety (MFDS) to initiate a Phase I clinical trial of PMC-403, its novel TIE2 agonistic antibody, for treating neovascular age-related macular degeneration (nAMD). The trial will be conducted as an open-label, multi-center study across multiple hospitals in South Korea, including Seoul National University Bundang Hospital, to assess safety, tolerability, and efficacy. PMC-403 represents the world's first TIE2 agonistic antibody to receive approval for an ophthalmology clinical trial, positioning it as a potential new therapeutic option for patients who have not responded to or relapsed from existing anti-VEGF treatments.PR NewswirePharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)PharmAbcine Inc., a South Korean clinical-stage biotech company, has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc.) to initiate a Phase I combination trial evaluating PMC-309, PharmAbcine's novel anti-VISTA antibody, in combination with KEYTRUDA (pembrolizumab) for multiple advanced solid tumors. Under the agreement, PharmAbcine will sponsor the study in Australia while MSD supplies KEYTRUDA. Preclinical data showed significantly enhanced tumor growth reduction with the combination therapy compared to either monotherapy, and the companies aim to address patients who don't respond well to existing immuno-oncology treatments.PR NewswirePharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM WeekPharmAbcine announced its participation in the 41st Annual J.P. Morgan Healthcare Conference and Biotech Showcase in January 2023 to hold one-on-one meetings with investors and pharmaceutical companies. The company aims to explore potential investment, licensing, and co-development opportunities for its pipeline assets, including olinvacimab, PMC-309, and PMC-403.PR NewswirePharmAbcine to participate in Jefferies 2022 London Healthcare ConferencePharmAbcine announced its participation in the Jefferies 2022 London Healthcare Conference, scheduled for November 15-17, 2022. The company plans to hold investor meetings with Dr. Jin-San Yoo to discuss drug development trends and investment opportunities. This event serves as a platform for PharmAbcine to engage with institutional investors and global executives.PR NewswirePharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022PharmAbcine Inc., a South Korean clinical-stage biotech company listed on KOSDAQ, announced it will present preclinical data for its anti-VISTA antibody candidate PMC-309 at the Society for Immunotherapy of Cancer Annual Meeting in Boston from November 8-12, 2022. The drug demonstrated significantly improved tumor growth inhibition when used in combination with an anti-PD-1 drug compared to monotherapies in nonclinical studies, and GLP-toxicology studies have been completed with no serious safety issues observed. The company plans to submit a Clinical Trial Application in late 2022.PR NewswirePharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in OphthalmologyPharmAbcine Inc. appointed Quan Dong Nguyen, an ophthalmology expert from Stanford University, to its Scientific Advisory Board to guide the development of its novel TIE2-activating antibody, PMC-403. The company aims to submit an Investigational New Drug (IND) application for this therapy in 2022, targeting patients with conditions like macular edema and neovascular AMD who do not respond well to existing anti-VEGF treatments.PR Newswire APACNuclixBio Announces a Collaborative Research Agreement with PharmAbcineNuclixBio and PharmAbcine signed a collaborative research agreement to develop novel mRNA therapeutics using NuclixBio's ringRNA platform. The drugs will express antibodies intracellularly to target human TIE2 receptors, aiming to improve therapeutic effect and patient convenience. Both companies expect the partnership to expand their pipeline assets.